In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the current treatment landscape for low-grade lymphomas, specifically follicular and mantle cell lymphoma.

Key Points Covered:

•⁠  ⁠Follicular Lymphoma: The discussion includes the minimum workup required for treatment planning, frontline treatment options, nuances of PFS with different anti-CD20 agents, and considerations for relapse or refractory cases.

•⁠  ⁠Mantle Cell Lymphoma: The conversation delves into initial treatment paradigms, the role of BTK inhibitors, considerations for TP53 mutations, and options for relapsed or refractory cases, including the growing importance of CAR T cell therapy.

Highlights:

•⁠  ⁠Treatment Options: From chemoimmunotherapy to novel agents like BTK inhibitors and CAR-T cell therapy, the podcast explores the evolving landscape of treatment options for these low-grade lymphomas.

•⁠  ⁠TP53 Mutations: The discussion sheds light on how treatment decisions are influenced by the presence of TP53 mutations, with a focus on recent studies and promising combinations.

•⁠  ⁠Relapse Management: Insights are shared on managing relapsed or refractory cases, including the role of BTK inhibitors, CAR-T cell therapy, and other emerging options.

Join the Oncology Brothers as they navigate through the complexities of treating low-grade lymphomas with expert insights from Dr. Torka. Stay informed about the latest advancements in oncology and the changing standards of care for these challenging diseases.

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com